Disofrol

Quick links to important sections

Disofrol

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Disofrol

Property Description
Active Ingredients Dexbrompheniramine and Pseudoephedrine
Form Oral tablet (including sustained-action), oral liquid (syrup)
Pharmacological Class Antihistamine and Decongestant Combination
General Purpose Relief from upper respiratory congestion and allergy symptoms
Origin Synthetic chemical substances

A Combination Drug for Upper Respiratory Symptoms

Disofrol is a synthetic pharmaceutical preparation formally classified as an Antihistamine and Decongestant Combination for systemic use, containing the active ingredients Dexbrompheniramine and Pseudoephedrine. This formulation utilizes a dual-action pairing for the relief of symptoms associated with seasonal allergies and the common cold. The medication represents an integrated class of products designed to address both the allergic trigger and the resulting physical symptoms, such as nasal obstruction, simultaneously.

The Composition and General Purpose

The two active components of Disofrol are entirely synthetic chemical substances; Dexbrompheniramine is an alkylamine derivative, and Pseudoephedrine is a sympathomimetic amine. A key differentiating factor of Disofrol and similar combinations is the availability of a sustained-action (extended-release) tablet form, which is designed to reduce dosing frequency while maintaining consistent symptom control. The combination of an antihistamine and a decongestant is intended to provide symptomatic relief for seasonal allergic rhinitis beyond what is typically achieved by using either ingredient alone.

The overall therapeutic purpose of this dual formulation is the relief of nasal obstruction, sinus pressure, and excessive nasal fluid production. This benefit stems from the components' complementary actions: the Dexbrompheniramine works to dry up secretions, while the Pseudoephedrine works to physically shrink swollen tissues by causing local vasoconstriction in the nasal mucosa.

Regulatory References

  1. Dexbrompheniramine and Pseudoephedrine Information

What side effects are possible with Disofrol?

Possible Side Effects and Safety Information

The official safety profile for the Dexbrompheniramine and Pseudoephedrine combination (Disofrol) is organized around frequency, affected systems, and specific safety constraints documented in regulatory labeling.

Adverse Reaction Classifications

Side effects are categorized by the physiological system involved and their reported occurrence rates. The most Common Adverse Reactions documented in official labeling relate to the Nervous System and Gastrointestinal Disorders, including drowsiness, dry mouth, insomnia, and dizziness.

System-Organ Class Common Reactions Serious Adverse Reactions (Label-Documented)
Nervous System Disorders Drowsiness, dizziness, insomnia, nervousness Seizure, confusion, hallucinations
Cardiac Disorders N/A Fast/irregular heart rate, increased blood pressure
Gastrointestinal Disorders Dry mouth/throat, loss of appetite N/A
Renal/Urinary Disorders N/A Painful or difficult urination

Key Safety Constraints and Special Populations

Official documents highlight that Serious Adverse Reactions primarily involve the cardiovascular and central nervous systems. These reactions, such as seizure and severe cardiac effects (irregular heartbeat, hypertension), require immediate attention.

Safety labeling includes explicit warnings regarding drug interactions; the combination is contraindicated for use during or within 14 days of stopping Monoamine Oxidase Inhibitor (MAOI) therapy. Caution is also specified for individuals with pre-existing conditions that may be worsened by the components, including severe hypertension, coronary artery disease, and glaucoma.

Population-Specific Notes indicate that older adults (aged 65 and over) may exhibit increased sensitivity to effects like dizziness and confusion, while children may be more sensitive to agitation and excitability.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents classify overdosage of this Antihistamine and Decongestant Combination as a potentially severe event, requiring immediate professional intervention. The documented manifestations are complex due to the combination of active components, resulting in effects on the Central Nervous System (CNS) that can range from stimulation to depression.

Overdose presentations officially cited include severe neurological signs like convulsions (seizures), hallucinations, unusual excitement, or restlessness. Cardiovascular system effects are also documented, including tachycardia (fast heartbeat), hypertension (increased blood pressure), and the potential for cardiac arrhythmias.

Regulatory labeling notes that overdosage carries a risk for severe outcomes, including death, a risk explicitly cited for infants and small children. Because of these documented life-threatening risks, official guidance strictly mandates that in case of accidental overdose, one must seek professional assistance or contact a Poison Control Center immediately.

Treatment is defined in the regulatory profile as symptomatic and supportive, which may include procedures such as gastric lavage or the use of intravenous short-acting barbiturates to manage severe CNS effects like seizures.

Therapeutic Uses of Disofrol

What Disofrol Treats: Main Uses and Benefits

Disofrol is a combination medication commonly used to help with symptoms related to allergic conditions and the common cold.

The formulation is indicated for use in contexts where short-term symptomatic assistance is appropriate. The medication is used in situations involving recurrent or episodic manifestations, primarily to support the management of symptoms associated with seasonal and perennial allergic rhinitis and acute upper respiratory episodes.

Relief from Allergic and Congestive Symptoms

Disofrol helps address symptom clusters that may become disruptive during flare-ups, such as the acute discomfort of a stuffy nose or the constant irritation of allergic rhinorrhea. Providing supportive relief in this area may assist with maintaining functional stability by contributing to improved comfort through the easing of the obstruction that affects nasal airflow. It is generally applied during phases when symptoms become more noticeable, offering supportive care for conditions like Upper Airway Cough Syndrome.


Quick Fact: Relief for Congestion and Sneezing This combination is often applied when symptoms include both nasal blockage and those related to irritative states.

Regulatory References

  1. Drug Facts Label from the NIH National Library of Medicine

Eligibility and Restrictions for Use

Who can and cannot use Disofrol?

The population eligibility for Disofrol (Dexbrompheniramine and Pseudoephedrine) is defined by official regulatory labeling, setting strict constraints on use based on age, concurrent medication, and pre-existing health conditions.

Eligibility Scope Status (Official Regulatory Statement)
Populations for whom use is allowed Adults and adolescents 12 years of age and older are the standard age group for established use.
Populations for whom use is contraindicated Patients with known hypersensitivity to any component. Use is prohibited if taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them. Contraindicated in patients with severe hypertension, severe coronary artery disease, narrow-angle glaucoma, or conditions causing urinary retention.
Populations for whom use is restricted Use requires caution in patients with non-severe heart disease, diabetes mellitus, hyperthyroidism, prostatic hypertrophy, or liver/kidney problems. Older adults must use with special caution.

Age-Related Eligibility Rules

The medicine is not recommended for use in children under 6 years of age. Furthermore, extended-release tablet forms are not recommended for children under 12 years of age.

Pregnancy and Lactation Eligibility Status

Use is generally not recommended during pregnancy and breastfeeding, and a health professional must be consulted before use.

What should I know about interactions with other medicines?

Disofrol Interactions with other medicines and products

Interaction Scope

Property Official Regulatory Statement
Medicinal product categories with documented interactions Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) Depressants, Sympathomimetic Agents, Tricyclic Antidepressants (TCAs), Ergot Alkaloids.
Specific interacting medicines (if explicitly listed) Isocarboxazid, Linezolid, Phenelzine, Selegiline, Tranylcypromine, Ergotamine, Dihydroergotamine.
Mechanistic basis of interactions (only if stated in label) Additive CNS depression (Pharmacodynamic), Reinforcement of sympathomimetic effects (Pharmacodynamic, risk of blood pressure increase).
Timing-based interaction rules (if applicable) The product must not be used if the patient is currently taking a prescription MAOI, or for 14 days after stopping the MAOI drug.
Population-specific interaction notes (if applicable) Geriatrics (Older Adults) may exhibit increased sensitivity to central nervous system effects such as drowsiness.
Interaction-related restrictions Restriction on co-administration with Alcoholic Beverages and substances that cause CNS depression.

Interaction Classifications (High-Level)

Property Official Regulatory Statement
Interaction severity classification (as defined in official documents) Contraindicated Combination (MAOIs, Ergot Alkaloids); Clinically Significant Interaction (CNS Depressants, Alcohol, other Sympathomimetics).
Regulatory basis FDA/NIH DailyMed Prescribing Information, National Health Authority Monographs.
Interaction-context constraints (as defined in official documents) Mandatory adherence to the 14-day mandatory separation window when discontinuing an MAOI prior to Disofrol administration.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the risk of severe blood pressure elevation.
  • The label requires a mandatory 14-day period to elapse between discontinuing an MAOI and starting Disofrol.
  • The combination with Ergot Alkaloids is contraindicated due to the potential for severe hypertensive reaction.
  • Co-administration with Alcohol and other Central Nervous System (CNS) Depressants may result in documented additive CNS depression.

Connection to the overall interaction profile (2–4 sentences): The official regulatory interaction structure for Disofrol is defined primarily by contraindications and pharmacodynamic reinforcement driven by the Pseudoephedrine component, alongside documented additive CNS depression from the Dexbrompheniramine component. This profile formally establishes specific prohibited combinations and requires adherence to a mandatory timing rule for substances with severe interaction potential. The regulatory data specifically details which classes of medicinal products and substances are documented to either severely prohibit use or reinforce existing effects, such as heightened blood pressure or increased central nervous system depression.

Mechanism of Action

Pharmacodynamic Mechanism

Disofrol acts through two complementary mechanisms to modulate physiological processes in the upper respiratory mucosa. The antihistamine component, Dexbrompheniramine, primarily functions as an antagonist at the Histamine H1 receptor, suppressing the histamine-driven inflammatory cascade and its resulting changes in capillary permeability and edema. A secondary mechanism involves blocking Muscarinic Acetylcholine Receptors, which limits glandular signaling and influences the regulation of fluid secretion and tissue stability in the mucosa.

The decongestant component, Pseudoephedrine, engages the alpha1-Adrenergic receptor on local blood vessels through direct and indirect agonism. This molecular interaction triggers the contraction of vascular smooth muscle, leading to vasoconstriction. This reduction in blood flow lowers the volume of the mucosal tissue, leading to a predictable physiological adjustment in the nasal airway resistance. The synergistic combination modulates both the inflammatory processes leading to fluid accumulation and the physical volume of the vascular bed simultaneously.

Dosage and Administration Information

How to Use Disofrol

Disofrol, a combination product containing Dexbrompheniramine and Pseudoephedrine, is administered via the oral route. The medication is available in several forms, including immediate-release (IR) tablets, oral solution, and sustained-action (extended-release) forms.


Dosing and Frequency

Standard adult administration for the immediate-release form consists of one dose (2 mg Dexbrompheniramine / 60 mg Pseudoephedrine) taken every 4 to 6 hours as needed. The maximum recommended for the immediate-release product is four doses in a 24-hour period. The dosing for the extended-release form is less frequent, generally based on the specific formulation's sustained action.


Administration Requirements

Instruction Category Procedural Constraint
Time of Day The final dose is often taken several hours before bedtime to minimize potential sleep interference from the stimulant component.
Form Handling Sustained-action tablets or capsules are swallowed whole and are not crushed, split, or chewed to maintain the controlled-release mechanism.
Liquid Dosing Oral solution is measured using a special dose-measuring device to ensure accurate dosage.

Population and Duration

Usage in children aged 6 to under 12 years involves a reduced dose, typically half the standard adult IR dose, administered at the same frequency. The medication is typically used for short-term relief of acute symptoms and is generally not taken for more than seven consecutive days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Disofrol

The clinical evaluation of Disofrol, a combination of an antihistamine and a decongestant, was studied in research examining symptom patterns for acute upper respiratory conditions. This overview summarizes the available study types, what those studies examined, and where research remains limited, drawing only on authoritative regulatory and scientific reports.


Evidence for Symptomatic Relief in Seasonal and Perennial Allergies

Research has explored the combination in contexts involving fluctuating or episodic manifestations associated with seasonal and perennial allergic rhinitis. Studies primarily relied on short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These trials were applied in studies examining short-term or episodic symptom patterns and monitored outcomes related to physical discomfort, such as patient-reported scores for overall symptom severity. Researchers measured changes in specific symptom axes, including sneezing, runny nose (rhinorrhea), and nasal congestion. Regulatory assessments classified the evidence base in this area as Moderate.


Evidence for Symptoms of the Common Cold and Upper Airway Cough Syndrome

Research examined the combination in contexts involving acute or disruptive episodes, specifically symptoms related to the common cold and Upper Airway Cough Syndrome (UACS). Systematic reviews and meta-analyses explored short-term symptom changes by analyzing findings from relevant trials. Studies monitored measured scores for nasal congestion and acute cough. Findings were reported regarding symptomatic changes observed during the study period, with follow-up durations mirroring the typical length of acute symptomatic episodes.


Research Uncertainty and Evidence Gaps

Limited information for long-term outcomes or the persistence of observed symptomatic changes beyond the acute phase exists, as study follow-up was typically constrained to 3 to 10 days. This focus indicates that long-term effects are not fully established.

A notable gap identified by official reviews is the limited research available in very young children (under age 6), where data are currently considered insufficient. Furthermore, studies explored the combination, but findings were mixed in fully separating the effects of the two active ingredients.

Key Studies & References Treatment of Allergic Rhinitis and Allergic Conjunctivitis (Clinical Review)

Frequently Asked Questions (FAQ)

Common questions about Disofrol (FAQ)


Q: How is Disofrol different from other drugs for the same condition?

Disofrol is distinguished as a combination product that contains two different categories of active ingredients: an antihistamine and a sympathomimetic decongestant. Furthermore, official product information highlights the availability of a sustained-action (extended-release) tablet form, which is designed to reduce the frequency of dosing required compared to immediate-release forms.


Q: What is the official definition of the condition Disofrol treats?

The primary condition Disofrol is indicated to treat, allergic rhinitis, is officially defined by key symptoms induced by allergens. These include watery discharge from the nose (rhinorrhea), nasal obstruction or congestion, sneezing, and nasal itching.


Q: What is the expected outcome after a full course of Disofrol?

Consistent with the medication’s indication, the intended outcome is the relief of acute upper respiratory symptoms. This includes improvements in common discomforts such as nasal congestion, sneezing, and excessive runny nose, which were the measured endpoints in clinical trials.


Q: How long does it typically take for Disofrol to start working?

Official pharmacokinetic information provides a guide for how quickly the medication acts in the body. For the antihistamine component, peak levels in the bloodstream are typically achieved within about five hours following a dose. This time frame indicates the point at which the concentration of the antihistamine component reaches its peak.


Q: How long does Disofrol stay in the body after the last dose?

The length of time Disofrol remains active in the body is estimated using the elimination half-life, which is a pharmacokinetic measure. For the antihistamine component (Brompheniramine), this half-life is reported in official sources to be approximately 25 hours.


Q: Does taking Disofrol with food change how it works?

Official administration guidelines indicate that Disofrol may be taken with food. This instruction is provided primarily for the user's comfort if taking the medicine causes stomach upset.


Q: Can Disofrol be taken with common over-the-counter pain relievers?

Regulatory documents caution against combining Disofrol with other over-the-counter cough and cold medicines. This is primarily a safety constraint to prevent taking too much of common pain relief ingredients (like ibuprofen or acetaminophen) which may be included in other cold remedies. Checking the active ingredients of any co-administered medicine is generally advised.


Q: Does Disofrol interact with herbal supplements like St. John's Wort?

Official regulatory documents indicate that interactions between this type of medication and many herbal supplements, such as St. John's Wort, have not been fully tested in clinical studies. For this reason, regulatory documents generally recommend caution, as the effects of combining these substances are not well-established in the official data.


Q: Are headaches a common side effect reported for Disofrol?

Headaches have been reported as a side effect associated with the use of the active antihistamine component, Brompheniramine. Official safety documentation lists this as one of the possible effects.


Q: What is the risk of having a serious side effect from Disofrol?

According to regulatory safety information, serious adverse reactions are generally classified as rare. These serious effects, which include issues like seizures or severe changes in heart rhythm, are explicitly listed in the official documents. This classification is provided to describe the nature and potential frequency of these effects.


Q: Do most people tolerate Disofrol well?

The patient tolerance profile is generally defined by the frequency and type of common adverse reactions listed in regulatory documents. These common reactions most often involve the central nervous system, such as drowsiness and nervousness, and the gastrointestinal system, particularly dry mouth.


Q: What is the success rate of Disofrol in clinical trials?

When evaluating the drug, clinical trials focused on measuring changes in patient-reported scores for overall symptom severity. Regulatory documents categorize the evidence base for Disofrol's efficacy in seasonal allergies as Moderate.


Q: If I feel better, can I stop taking Disofrol?

Disofrol is designated for short-term use, consistent with the temporary nature of acute cold or allergy symptoms. The official regulatory limit advises against taking the medication for more than seven consecutive days. Extended use beyond the recommended duration is not supported by official product information.


Q: What happens if a person misses a dose of Disofrol?

Official patient instructions indicate that a missed dose is generally taken as soon as possible, if remembered. If the next scheduled dose is due shortly, skipping the missed dose is usually advised. This guidance is provided to help ensure the maximum daily limit is not exceeded.


Q: What should I do if I accidentally take two doses of Disofrol?

Regulatory documents detail the potential consequences of exceeding the recommended dose. Taking more than the maximum daily amount can lead to serious effects, including symptoms such as seizures, severe high blood pressure, or irregular heartbeat. Exceeding the recommended dosage limit is advised to be avoided.

How should Disofrol be stored and disposed of?

How to Store and Dispose of Disofrol?

Disofrol (Dexbrompheniramine and Pseudoephedrine) must be stored according to official regulatory requirements to maintain product stability and safety.


Official Storage Conditions

Store this medication at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from light and excess moisture; do not store it in the bathroom. Liquid forms must not be frozen. Keep the medicine in its original container with the cap tightly closed.


Child-Safety and Disposal

Keep Disofrol out of the reach of children and pets, storing it in a secure location. Dispose of unused or expired medicine using a drug take-back program. If a program is unavailable, follow the FDA's household trash procedure by mixing the medicine with an undesirable substance, sealing it, and discarding it in the trash. Do not flush Disofrol down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Disofrol found in:

A-Z Index: